J. Llovet, A. Burroughs, and J. Bruix, Hepatocellular carcinoma, The Lancet, vol.362, issue.9399, pp.1907-1917, 2003.
DOI : 10.1016/S0140-6736(03)14964-1

J. Bruix, M. Sherman, J. Llovet, M. Beaugrand, R. Lencioni et al., Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference, Journal of Hepatology, vol.35, issue.3, pp.421-430, 2001.
DOI : 10.1016/S0168-8278(01)00130-1

J. Bruix and J. Llovet, Prognostic prediction and treatment strategy in hepatocellular carcinoma, Hepatology, vol.34, issue.3, pp.519-524, 2002.
DOI : 10.1053/jhep.2002.32089

J. Llovet, D. Bisceglie, A. Bruix, J. Kramer, B. Lencioni et al., Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma, JNCI Journal of the National Cancer Institute, vol.100, issue.10, pp.698-711, 2008.
DOI : 10.1093/jnci/djn134

J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in Advanced Hepatocellular Carcinoma, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma, pp.378-390, 2008.
DOI : 10.1056/NEJMoa0708857

E. Curtit, A. Thiery-vuillemin, T. Nguyen, B. Heyd, X. Pivot et al., Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular Carcinoma: A Case Report, Journal of Clinical Oncology, vol.29, issue.12, pp.330-332, 2011.
DOI : 10.1200/JCO.2010.32.6785

J. Bruix and M. Sherman, Management of hepatocellular carcinoma, Hepatology, vol.35, issue.5, pp.1208-1236, 2005.
DOI : 10.1002/hep.20933

G. Torzilli, J. Belghiti, N. Kokudo, T. Takayama, L. Capussotti et al., A snapshot of the effective indications and results of surgery for http, p.171

S. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. Mcnabola et al., BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, BAY 43?9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis, pp.7099-7109, 2004.
DOI : 10.1158/0008-5472.CAN-04-1443

A. Cheng, Y. Kang, Z. Chen, C. Tsao, S. Qin et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, The Lancet Oncology, vol.10, issue.1, pp.25-34, 2009.
DOI : 10.1016/S1470-2045(08)70285-7

S. Irtan, X. Chopin-laly, M. Ronot, S. Faivre, V. Paradis et al., Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection, Liver International, vol.5, issue.5, pp.740-743, 2011.
DOI : 10.1111/j.1478-3231.2010.02441.x

L. Barbier, F. Muscari, L. Guellec, S. Pariente, A. Otal et al., Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib, International Journal of Hepatology, vol.15, pp.7910-7913, 2011.
DOI : 10.1186/1471-2407-9-208

L. Tarantino, G. Francica, I. Sordelli, F. Esposito, G. A. Sorrentino et al., Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy, Abdominal Imaging, vol.215, issue.5, pp.537-544, 2006.
DOI : 10.1007/s00261-005-0150-x

F. Piscaglia, A. Gianstefani, M. Ravaioli, R. Golfieri, A. Cappelli et al., Bologna Liver Transplant Group: Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation, Liver Transpl, vol.16, pp.658-667, 2010.

Q. Li, B. Xu, L. Fu, and X. Hao, Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma, J Exp Clin Cancer Res, vol.25, pp.403-409, 2006.

L. Barbier, D. Fuks, P. Pessaux, F. Muscari, L. Treut et al., Safety of Liver Resection for Hepatocellular Carcinoma After Sorafenib Therapy: A Multicenter Case-Matched Study, Annals of Surgical Oncology, vol.83, issue.11, 2013.
DOI : 10.1245/s10434-013-3029-z

. Rahali, Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib, World Journal of Surgical Oncology, vol.11, issue.1, p.171, 2013.
DOI : 10.1245/s10434-013-3029-z
URL : https://hal.archives-ouvertes.fr/inserm-00850497